Degenerative ArthritisNCT03247023
Long Term Follow-up of Integra® Cadence™ Total Ankle System in Primary Ankle Joint Replacement
An observational study of Degenerative Arthritis and Rheumatoid Arthritis, run by Smith & Nephew, Inc. at 6 sites in 5 countries.
Trial summary
This study will evaluate the long term performance and safety data for the Cadence™ Total Ankle System (CTAS) when used for primary arthroplasty in patients with primary arthritis (e.g. degenerative disease), secondary arthritis (e.g. Read more about this study
- Who is it for?
- Ages 19 years and older
- Conditions the study is for
- Degenerative Arthritis, Rheumatoid Arthritis, Traumatic Arthritis
- What is being tested?
- Implantation of Integra Cadence Total Ankle System
- Type of treatment
- Medical device
- How many people
- 65 participants
- Where
- 6 sitesin 5 countries
- Study dates
- 18 Sep 2017to 6 Sep 2023
- Phase
- Observational
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patient with ankle arthritis requiring total ankle replacement
Who may be able to join
- Subjects will be included if he/she:
- Is > 18 years of age.
- Is skeletally mature.
- Qualifies for primary TAR per the surgeon and has a diagnosis of one of the following: primary arthritis (e.g. degenerative disease), secondary arthritis (e.g. post-traumatic, avascular necrosis, if minimally 2/3 of the talus is preserved), or systemic arthritis of the ankle (e.g. rheumatoid arthritis, hemochromatosis).
- Is suitable for TAR with CTAS per the study surgeon based on the product indication and having considered deformity, stability, bone quality, soft- tissue envelope, and neurovascular status.
- Is willing and able to cooperate in the required post-operative therapy.
- Is willing and able to complete scheduled follow-up visits, evaluations, and questionnaires as described in the Informed Consent or Information Letter and Data Transfer Authorization Form, as applicable.
- Reads, understands and signs the Ethical Committee approved Informed Consent or Information Letter and Data Transfer Authorization Form, as applicable
Who cannot join
- Subjects will be excluded from the study if he/she:
- Is Morbidly Obese (defined by BMI > 40 or BMI of 35 - 40 with significant medical problems caused by or made worse by their weight).
- Is an active nicotine user (smoking, chewing, smokeless tobacco, patch) and unwilling to cease nicotine use within 1 month prior to surgery, and 2 months post-surgery.
- Has one of the following conditions, which could compromise the affected limb: ankle arthrodesis with malleolar exeresis, severe neurological (Charcot's Arthropathy) or vascular disease, loss of musculature or neuromuscular compromise.
- Has an active local/systemic infection that may affect the prosthetic joint or has a recent history of infection.
- Continues on long-term medication, which may compromise bone stock (e.g. undergoing immunosuppressive therapy, long-term steroids) and is unable to cease medication usage from 3 weeks prior to surgery to 3 weeks post-surgery.
Show all 16Show fewer
- Has a condition that may impair proper wound healing (e.g., poor soft tissue envelope).
- Had previous ankle surgery and/or injury that has adversely affected the anklebone stock.
- Has had or is scheduled to have contralateral TAR surgery.
- Is pregnant or plans to become pregnant during the follow up period.
- Has a metabolic disorder or disease that may compromise bone quality (e.g. arthrogryposis etc.), physiological or anatomical anomalies, and/or malignancy/local bone tumors.
- Has severe avascular necrosis of the talus/tibia.
- Has inadequate neuromuscular status (e.g., prior paralysis, severe neuropathy).
- Has a known sensitivity or allergic reaction to one or more of the implanted materials.
- Is a poor candidate for general anesthesia.
- Is a prisoner, mentally incompetent or unable to understand what participation in this study entails, a known alcohol or drug abuser, or anticipated to be non- compliant.
Trial locations and contacts
6 sites in 5 countries.
6 sites in 5 countries
Belgium2 sites
Universitair Ziekenhuis Gent
Ghent, 9000
Foot and Ankle Institute
Woluwe-St-Lambert, B-1200
United Kingdom1 site
North Cumbria University Hospitals
Carlisle, CA2 7HY
About this study
This study will evaluate the long term performance and safety data for the Cadence™ Total Ankle System (CTAS) when used for primary arthroplasty in patients with primary arthritis (e.g. degenerative disease), secondary arthritis (e.g. post-traumatic, avascular necrosis, if minimally 2/3 of the talus is preserved), and systemic arthritis of the ankle (e.g. rheumatoid arthritis, hemochromatosis)
- Being tested
- Implantation of Integra Cadence Total Ankle System
- Medical subject headings
- Osteoarthritis, Arthritis, Rheumatoid
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Implantation of Integra Cadence Total Ankle SystemDevice
Primary Ankle Arthroplasty
| Study group | Role | What they receive |
|---|---|---|
| Integra Cadence Total Ankle System | Not described Receives: Device: Implantation of Integra Cadence Total Ankle System |
What is being measured
The primary outcome is the main question the study is designed to answer.
Implant Survivorship at 2 Years
Implant survivorship determined by the percentage of participants with survival of the device. Successful device survival was defined as absence of device removal or revision.
Measured: 2 years
Secondary outcomes (18)
Implant Survivorship at 5 Years and 10 Years
Implant survivorship at 5 years and 10 years was determined by the percentage of participants with device survival. Survivorship was measured using a Kaplan-Meier survival estimate with survival defined as absence of device removal or revision.
Measured: 5 years and 10 years
Patient Reported Outcomes Measurement Information System (PROMIS) Physical Function (PF) - Mobility
The PROMIS - Physical Function and Mobility score consisted of 15 components on a 5-point Likert scale. Responses were combined to produce a score that ranged from 0 to 100 where higher values represented higher mobility (i.e., a higher score was a better outcome).
Measured: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years
Foot and Ankle Ability Measure (FAAM) Activities of Daily Living (ADL) Subscale
The Foot and Ankle Ability Measure (FAAM) Activities of Daily Living (ADL) Subscale scored 21 components on a 5-point Likert scale. Score totals ranged from 0 to 84 and were transformed to percentage scores with 100 representing no dysfunction (i.e., a higher score was a better outcome).
Measured: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years
Visual Analogue Scale (VAS) Pain Score: Resting
A Visual Analogue Scale (VAS) assessment was used to rate ankle pain while resting. The participant would indicate the level of pain by placing a vertical mark on a 100mm scale. Scores ranged from 0 to 100 with higher scores indicating a higher level of pain (i.e., a higher score was a worse outcome).
Measured: Baseline, 6 weeks, 3 months, 6 months, 1 year, 2 years, 5 years
Visual Analogue Scale (VAS) Pain Score: Activity
A Visual Analogue Scale (VAS) assessment was used to rate ankle pain while during activity. The participant would indicate the level of pain by placing a vertical mark on a 100mm scale. Scores ranged from 0 to 100 with higher scores indicating a higher level of pain (i.e., a higher score was a worse outcome).
Measured: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years
Short Form-36 Version 2 Health Survey (SF-36v2): Physical Functioning
The SF-36v2 Health Survey is composed of 36 questions across 8 domains. The Physical Functioning domain focused on limitations in daily activities like running, climbing stairs, bending, or walking. Scores ranged from 0 to 100 with lower scores indicating greater physical disability (i.e., a higher score was a better outcome).
Measured: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years
Short Form-36 Version 2 Health Survey (SF-36v2): Role Limitations Due to Physical Health
The SF-36v2 Health Survey is composed of 36 questions across 8 domains. The Role Limitations Due to Physical Health domain focused on limitations in work or other regular daily activities as a result of their physical health. Scores ranged from 0 to 100 with lower scores indicating greater limitation (i.e., a higher score was a better outcome).
Measured: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years
Short Form-36 Version 2 Health Survey (SF-36v2): Role Limitations Due to Emotional Problems
The SF-36v2 Health Survey is composed of 36 questions across 8 domains. The Role Limitations Due to Emotional Problems domain focused on limitations in work or other regular daily activities as a result of any emotional problems such as feeling depressed or anxious. Scores ranged from 0 to 100 with lower scores indicating greater limitation (i.e., a higher score was a better outcome).
Measured: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years
Short Form-36 Version 2 Health Survey (SF-36v2): Energy/Fatigue
The SF-36v2 Health Survey is composed of 36 questions across 8 domains. The Energy/Fatigue domain focused on feelings of energy, tiredness, and being worn out over the past four weeks. Scores ranged from 0 to 100 with lower scores indicating less energy and more fatigue (i.e., a higher score was a better outcome).
Measured: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years
Short Form-36 Version 2 Health Survey (SF-36v2): Emotional Well-being
The SF-36v2 Health Survey is composed of 36 questions across 8 domains. The Emotional Well-being domain focused on feelings of their mental health over the past four weeks. Scores ranged from 0 to 100 with lower scores indicating poor emotional well-being (i.e., a higher score was a better outcome).
Measured: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years
Short Form-36 Version 2 Health Survey (SF-36v2): Social Functioning
The SF-36v2 Health Survey is composed of 36 questions across 8 domains. The Social Functioning domain focused on how physical health or emotional problems interfered with their social activities (like visiting with friends, relatives, etc.). Scores ranged from 0 to 100 with lower scores indicating greater disfunction (i.e., a higher score was a better outcome).
Measured: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years
Short Form-36 Version 2 Health Survey (SF-36v2): Pain
The SF-36v2 Health Survey is composed of 36 questions across 8 domains. The Pain domain focused on how much pain affected daily activities over the last four weeks. Scores ranged from 0 to 100 with lower scores indicating more pain (i.e., a higher score was a better outcome).
Measured: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years
Short Form-36 Version 2 Health Survey (SF-36v2): General Health
The SF-36v2 Health Survey is composed of 36 questions across 8 domains. The General Health domain focused on perception of overall health and health change over time. Scores ranged from 0 to 100 with lower scores indicating worse health (i.e., a higher score was a better outcome).
Measured: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years
Short Form-36 Version 2 Health Survey (SF-36v2): Physical Component Score
The SF-36v2 Health Survey is composed of 36 questions across 8 domains. The Physical Component score combined scores from the Physical Functioning, Role Limitations Due to Physical Health, Pain, and General Health domains. Scores ranged from 0 to 100 with lower scores indicating worse physical health (i.e., a higher score was a better outcome).
Measured: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years
Short Form-36 Version 2 Health Survey (SF-36v2): Mental Component Score
The SF-36v2 Health Survey is composed of 36 questions across 8 domains. The Physical Component score combined scores from the Role Limitations Due to Emotional Problems, Energy/Fatigue, Emotional Well-being, and Social Functioning domains. Scores ranged from 0 to 100 with lower scores indicating worse mental health (i.e., a higher score was a better outcome).
Measured: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years
Radiographic Success
The number of participants with radiographic success were categorized as either 'Fail' or 'Success'. Success was defined as absence of implant radiolucency, subsidence, tilting, and/or migration with failure specifically defined as occurring if:
- ≥3 of the 20 radiolucency zones had >4mm in width, OR
- device tilting = present, OR
- device subsidence (tibial OR talar) = >4mm, OR
- device migration (tibial OR talar) = >4mm
Measured: 6 weeks, 3 months, 6 months, 1 year, 2 years, 5 years
Radiographic Assessment: Ankle Dorsiflexion and Plantarflexion Range of Motion
Range of motion measurements for ankle dorsiflexion and ankle plantarflexion in degrees were derived from radiographs in positions of maximum plantarflexion and dorsiflexion.
Measured: Baseline, 1 year, 2 years
Radiographic Assessment: Tibiotalar Range of Motion
Range of motion measurements were derived from radiographs in positions of maximum plantarflexion and dorsiflexion. Tibiotalar range of motion in degrees was calculated as the difference between the ankle dorsiflexion and ankle plantarflexion angles.
Measured: Baseline, 1 year, 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Aug 2017
- Study start18 Sep 2017
- Primary completion6 Sep 2023
- Study completion6 Sep 2023
Why it stopped: Sponsor decision not related to safety
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Degenerative ArthritisStudies of the same condition, open and under way.
- More trials run by Smith & Nephew, Inc.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 65 participants (actual)
Sponsor and investigators
- Lead sponsor
- Smith & Nephew, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Smith & Nephew Orthopaedics AG
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03247023
- Sponsor's protocol ID
- T-CTAS-002
- Status last verified
- Dec 2024
- First submitted
- 8 Aug 2017
- Last updated
- 22 Jun 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 22 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Long Term Follow-up of Integra® Cadence™ Total Ankle System in Primary Ankle Joint Replacement
- ClinicalTrials.gov ID
- NCT03247023
- Acronym / sponsor ID
- T-CTAS-002
- Study type
- Observational
- Recruitment status
- TerminatedReason stopped: Sponsor decision not related to safety
- Enrolment
- 65 participants (actual)
- Lead sponsor
- Smith & Nephew, Inc.Industry (pharma, biotech, devices)
- Collaborators
- Smith & Nephew Orthopaedics AG
- Study start
- 18 Sep 2017 (actual)
- Primary completion
- 6 Sep 2023 (actual)
- Study completion
- 6 Sep 2023 (actual)
- First posted
- 11 Aug 2017 (actual)
- Results
- Posted 22 Jun 2026
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will evaluate the long term performance and safety data for the Cadence™ Total Ankle System (CTAS) when used for primary arthroplasty in patients with primary arthritis (e.g. degenerative disease), secondary arthritis (e.g. post-traumatic, avascular necrosis, if minimally 2/3 of the talus is preserved), and systemic arthritis of the ankle (e.g. rheumatoid arthritis, hemochromatosis)
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Integra Cadence Total Ankle System | – | Device: Implantation of Integra Cadence Total Ankle System |
Who may qualify
- Ages
- 19 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patient with ankle arthritis requiring total ankle replacement
Key inclusion criteria (8 listed)
- Is > 18 years of age.
- Is skeletally mature.
- Qualifies for primary TAR per the surgeon and has a diagnosis of one of the following: primary arthritis (e.g. degenerative disease), secondary arthritis (e.g. post-traumatic, avascular necrosis, if minimally 2/3 of the talus is preserved), or systemic arthritis of the ankle (e.g. rheumatoid arthritis, hemochromatosis).
- Is suitable for TAR with CTAS per the study surgeon based on the product indication and having considered deformity, stability, bone quality, soft- tissue envelope, and neurovascular status.
- Is willing and able to cooperate in the required post-operative therapy.
Key exclusion criteria (16 listed)
- Is Morbidly Obese (defined by BMI > 40 or BMI of 35 - 40 with significant medical problems caused by or made worse by their weight).
- Is an active nicotine user (smoking, chewing, smokeless tobacco, patch) and unwilling to cease nicotine use within 1 month prior to surgery, and 2 months post-surgery.
- Has one of the following conditions, which could compromise the affected limb: ankle arthrodesis with malleolar exeresis, severe neurological (Charcot's Arthropathy) or vascular disease, loss of musculature or neuromuscular compromise.
- Has an active local/systemic infection that may affect the prosthetic joint or has a recent history of infection.
- Continues on long-term medication, which may compromise bone stock (e.g. undergoing immunosuppressive therapy, long-term steroids) and is unable to cease medication usage from 3 weeks prior to surgery to 3 weeks post-surgery.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Implantation of Integra Cadence Total Ankle SystemPrimary Ankle Arthroplasty | Device | Integra Cadence Total Ankle System |
Primary outcome
Implant Survivorship at 2 Years
Time frame: 2 years
Implant survivorship determined by the percentage of participants with survival of the device. Successful device survival was defined as absence of device removal or revision.
18 secondary outcomes
Implant Survivorship at 5 Years and 10 Years
Time frame: 5 years and 10 years
Patient Reported Outcomes Measurement Information System (PROMIS) Physical Function (PF) - Mobility
Time frame: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years
Foot and Ankle Ability Measure (FAAM) Activities of Daily Living (ADL) Subscale
Time frame: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years
Visual Analogue Scale (VAS) Pain Score: Resting
Time frame: Baseline, 6 weeks, 3 months, 6 months, 1 year, 2 years, 5 years
Visual Analogue Scale (VAS) Pain Score: Activity
Time frame: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years
Short Form-36 Version 2 Health Survey (SF-36v2): Physical Functioning
Time frame: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years
Short Form-36 Version 2 Health Survey (SF-36v2): Role Limitations Due to Physical Health
Time frame: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years
Short Form-36 Version 2 Health Survey (SF-36v2): Role Limitations Due to Emotional Problems
Time frame: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years
Short Form-36 Version 2 Health Survey (SF-36v2): Energy/Fatigue
Time frame: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years
Short Form-36 Version 2 Health Survey (SF-36v2): Emotional Well-being
Time frame: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years
Short Form-36 Version 2 Health Survey (SF-36v2): Social Functioning
Time frame: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years
Short Form-36 Version 2 Health Survey (SF-36v2): Pain
Time frame: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years
Short Form-36 Version 2 Health Survey (SF-36v2): General Health
Time frame: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years
Short Form-36 Version 2 Health Survey (SF-36v2): Physical Component Score
Time frame: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years
Short Form-36 Version 2 Health Survey (SF-36v2): Mental Component Score
Time frame: Baseline, 3 months, 6 months, 1 year, 2 years, 5 years
Radiographic Success
Time frame: 6 weeks, 3 months, 6 months, 1 year, 2 years, 5 years
Radiographic Assessment: Ankle Dorsiflexion and Plantarflexion Range of Motion
Time frame: Baseline, 1 year, 2 years
Radiographic Assessment: Tibiotalar Range of Motion
Time frame: Baseline, 1 year, 2 years
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jun 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: Undecided
Related trials for Degenerative Arthritis
Not yet recruiting
Holistic Healing for Knee Osteoarthritis
Knee Osteoarthritis (Knee OA)
Active, not recruiting
Effectiveness of Therapeutic Exercises on Spinopelvic Mobility
Osteoarthritis (OA) of the Hip
Recruiting
Effect of Anti-inflammatory Diet in Osteoarthritis
Osteoarthritis, Knee
Active, not recruitingPhase 2/3
Single vs Triple Hyaluronic Acid in Knee Osteoarthritis
Osteoarthritis, Knee
Not yet recruiting
The Feasibility of a Virtual/Home-based OA Treatment Program in Older Adults With OA and Multimorbidity
Osteoarthritis of the Knee
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
6 sites in 5 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Degenerative Arthritis and Rheumatoid Arthritis, run by Smith & Nephew, Inc. at 6 sites in 5 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 22 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 6 sites in Belgium, Canada, France, Spain, United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 22 Jun 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Implant Survivorship at 2 Years (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jun 2026.